Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
FBDT$1.01+0.03(+2.54%)First Breach Advances Ammunition and Drone Manufacturing Expansion as U.S. Reshoring Accelerates[8:31:00 AM ET]ICMFF$0.04+0.00(+1.45%)Iconic Minerals Reports Further Positive Near-Surface Gold and Silver Results from Final 2026 Drill Assays at New Pass, Nevada[8:30:00 AM ET]ISBA$39.37+0.01(+0.03%)Isabella Bank Corporation Reports Record Third Quarter 2026 Earnings[8:30:00 AM ET]IPFX$10.100.00(0.00%)Quantum Space and Inflection Point Acquisition Corp. VI Announce Effectiveness of Registration Statement Ahead of Planned Business Combination and NYSE Listing Quantum Space, LLC (the "Company" or "Quantum Space"), a company developing the next generation of advanced maneuverable spacecraft for national...[8:30:00 AM ET]TNON$2.19-0.07(-3.10%)Tenon Medical, Inc. Sets Date for Third Quarter 2026 Earnings[8:30:00 AM ET]LUCD$0.41+0.00(+0.39%)Lucid Diagnostics to Hold Third Quarter 2026 Business Update Conference Call and Webcast on November 12, 2026 Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of ...[8:30:00 AM ET]ORBS$0.82+0.04(+5.13%)Eightco Holdings (ORBS) Announces Strategic Monetization to Demonstrate Portfolio Gains and Support Accelerated Buybacks Eightco Holdings Inc. (NASDAQ: ORBS) ("Eightco" or the "Company") today announced that it has repurchased more than 55 million shares of its common...[8:30:00 AM ET]DOGZ$0.69+0.04(+5.55%)Dogness's Rechargeable Pet Repellent Mat Maintains Top Three Ranking on Amazon U.S. Dogness (International) Corporation ("Dogness" or the "Company") (NASDAQ: DOGZ), a developer and manufacturer of a comprehensive line of...[8:30:00 AM ET]GOAI$0.97+0.06(+6.52%)Eva Live (NASDAQ: GOAI) Introduces EvaFarmSight for Precision Agriculture Market Projected to Reach $38.8 Billion[8:30:00 AM ET]ONDS$6.72-0.14(-2.04%)Ondas to Report Third Quarter 2026 Financial Results on November 12, 2026 at 8:30 AM ET[8:30:00 AM ET]MLSS$0.32+0.02(+5.67%)Milestone Scientific Provides Major Commercial Growth Update as CompuFlo® Expands Across 30 Million+ Annual Global Epidural Procedures[8:30:00 AM ET]HQI$16.85-0.34(-1.98%)HireQuest to Hold Third Quarter 2026 Financial Results Conference Call on Thursday, November 12, 2026 HireQuest (Nasdaq: HQI), a national franchisor of on-demand staffing and direct-hire recruiting services, today announced that it will hold a...[8:30:00 AM ET]AZTR$0.88-0.03(-2.84%)Azitra, Inc. Expands Eligibility for ATR-04 Phase 1/2 Clinical Trial to Include Patients with Rashes due to KRAS and MEK Inhibitors Azitra, Inc. ("Azitra" or the "Company") (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies ...[8:30:00 AM ET]PBK$0.15+0.01(+3.81%)PowerBank Announces First 2 MW Modular Data Center in Ontario with Potential Annual Lease Revenue of Approximately C$2 Million PowerBank Corporation (Nasdaq: PBK) (Cboe CA: PBK) (FSE: 103) ("PowerBank" or the "Company"), a leader in independent energy development and asset...[8:30:00 AM ET]CTW$1.79+0.08(+4.68%)CTW to Participate in the BMO Capital Markets Technology and Innovation Leaders Conference[8:30:00 AM ET]IGCRF$0.240.00(0.00%)Integrated Quantum Technologies and Inverite Insights Sign Pilot Agreement to Advance Privacy-Preserving AI in Financial Services; IQT Announces Digital Marketing Agreement[8:30:00 AM ET]

RGNX · NASDAQ

REGENXBIO Inc.

$7.07 -0.17 (-2.35%)

Company overview

REGENXBIO Inc. is a clinical-stage biotechnology company that develops gene therapy product candidates designed to deliver genes to cells to address genetic defects or enable cells in the body to produce therapeutic proteins or antibodies intended to impact disease. Its gene therapy product candidates are based on the NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in a Phase III clinical trial for the treatment of wet age-related macular degeneration.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$467M
Employees
353
Headquarters
Rockville, MD
Website
regenxbio.com
CEO
Curran Simpson
Listed
September 17, 2015
P/E
-1.26
Dividend yield
0.00%

Company financials

Revenue
$87.8M
Gross profit
-$120,000
Operating income
-$257M
EBITDA
-$235M
Net income
-$290M
EPS
-$5.60
Total assets
$342M
Total debt
$71.1M
Gross margin
-0.14%
Net margin
-330.23%
Earnings yield
-79.21%

Revenue segmentation

By product (FY 2025)
By region (FY 2025)

No geographic segmentation.

Showing FY 2025

Price chart

5.047.8510.6713.4816.30
RGNX 1D NASDAQ O6.52H7.29L6.51C7.24+0.64 (+9.70%)Vol534.42K

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
Ticker Type Headline Source Published
RGNXREGENXBIO Inc. Press release REGENXBIO to Host Conference Call on November 5 to Discuss Third Quarter 2026 Financial Results and Operational Highlights REGENXBIO Inc. PR Newswire
RGNXREGENXBIO Inc. Stock news Critical Survey: REGENXBIO (NASDAQ:RGNX) versus Vir Biotechnology (NASDAQ:VIR) Defense World
RGNXREGENXBIO Inc. Press release REGENXBIO to Host Investor Event Highlighting Surabgene Lomparvovec (Sura-vec) in Wet AMD on October 20 REGENXBIO Inc. (Nasdaq: RGNX) today announced it will host an investor event at 1:00 p.m. PR Newswire
RGNXREGENXBIO Inc. Press release REGENXBIO Presents Positive Three-Year Durability Data for Surabgene Lomparvovec in Diabetic Retinopathy at Retina Society Annual Scientific Meeting PR Newswire
RGNXREGENXBIO Inc. Stock news REGENXBIO Inc. (RGNX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Seeking Alpha
RGNXREGENXBIO Inc. Press release REGENXBIO to Participate in Upcoming Investor Conferences PR Newswire
RGNXREGENXBIO Inc. Legal Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of REGENXBIO Inc. (RGNX) GuruFocus
RGNXREGENXBIO Inc. Legal Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of REGENXBIO Inc. (RGNX) Business Wire
RGNXREGENXBIO Inc. Stock news RGNX Stock Slumps 25% on FDA Clinical Hold for RGX-121 Gene Therapy Zacks Investment Research
RGNXREGENXBIO Inc. Stock news Regenxbio: Sell-Off On Hunter Setback Presents A Risky Buy Opportunity Seeking Alpha
RGNXREGENXBIO Inc. Press release REGENXBIO Strengthens Board of Directors with Appointment of Greg Ciongoli PRNewsWire
RGNXREGENXBIO Inc. Legal RGNX Investor Notice: Johnson Fistel Investigates REGENXBIO Inc. Following Clinical Hold GlobeNewsWire
RGNXREGENXBIO Inc. Stock news Crude Oil Down 3%; XPeng Shares Fall After Q2 Results Benzinga
RGNXREGENXBIO Inc. Stock news Regenxbio Stock Sinks 22% Following Surprise Finding in Gene Therapy Trial Barrons
RGNXREGENXBIO Inc. Stock news FDA places clinical hold on Regenxbio's gene therapy for Hunter Syndrome Reuters
RGNXREGENXBIO Inc. Press release REGENXBIO Announces Regulatory Update on RGX-121 for MPS II PRNewsWire
RGNXREGENXBIO Inc. Stock news Regenxbio's Multi-Catalyst Setup Is Hard To Ignore (Rating Upgrade) Seeking Alpha
RGNXREGENXBIO Inc. Stock news REGENXBIO Q2 Earnings Call Highlights MarketBeat
RGNXREGENXBIO Inc. Stock news REGENXBIO Inc. (RGNX) Q2 2026 Earnings Call Transcript Seeking Alpha
RGNXREGENXBIO Inc. Stock news Regenxbio (RGNX) Beats Q2 Earnings and Revenue Estimates Zacks Investment Research
See more
FAQ

Questions about REGENXBIO Inc.

What does REGENXBIO Inc. do?
REGENXBIO Inc. is a clinical-stage biotechnology company that develops gene therapy product candidates designed to deliver genes to cells to address genetic defects or enable cells in the body to produce therapeutic proteins or antibodies intended to impact disease. Its gene therapy product candidates are based on the NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in a Phase III clinical trial for the treatment of wet age-related macular degeneration.
What is RGNX's market cap?
REGENXBIO Inc. (RGNX) is a listed stock with a live quote. The latest market cap on this page is $467M.
Where is REGENXBIO Inc. headquartered?
REGENXBIO Inc. is headquartered in Rockville, MD.
How do I get RGNX news from the API?
Call GET /v1/news?tickers=RGNX. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search the full archive in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees the full archive.
How far back does RGNX news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for RGNX, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees the full archive as headlines are ingested. A Free API key returns the last year. Pro keys search the full archive.
Is the RGNX price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 1,000 REST requests a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs